Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 23 Jan 2020
Health Technology Assessment around the world: broadening the understanding of cross-country differences
22 January 2020 - Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, ...
Posted by Michael Wonder on 22 Jan 2020
Reimbursement for Repatha to expand treatment options for ASCVD patients
22 January 2020 - Amgen is set to expand treatment options for atherosclerotic cardiovascular disease patients with Repatha, a high-cholesterol treatment, ...
Posted by Michael Wonder on 22 Jan 2020
NHS patients denied new lung cancer drug after another NICE deadlock
22 January 2020 - Certain untreated lung cancer patients on England’s NHS will have to make do with older drugs ...
Posted by Michael Wonder on 22 Jan 2020
NICE rejects Janssen’s Stelara on cost efficiency grounds
22 January 2020 - NICE has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ...
Posted by Michael Wonder on 20 Jan 2020
After 20 years of using economic evaluation, should NICE be considered a methods innovator?
13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...
Posted by Michael Wonder on 19 Jan 2020
Closing the cycle of innovation in health care in Europe
17 January 2020 - Pragmatic or practice-oriented comparative effectiveness trials may be conducted to fill the evidence gaps that are revealed ...
Posted by Michael Wonder on 17 Jan 2020
Use of patient preference studies in HTA decision making: a NICE perspective
16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee ...
Posted by Michael Wonder on 17 Jan 2020
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...
Posted by Michael Wonder on 16 Jan 2020
Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children
15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...
Posted by Michael Wonder on 16 Jan 2020
NICE ‘OK’ for Lynparza
16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, ...
Posted by Michael Wonder on 16 Jan 2020
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
15 January 2020 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 16 Jan 2020
Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit
15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...
Posted by Michael Wonder on 15 Jan 2020
Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations
14 January 2020 - HTA recommendations vary widely throughout Europe, even for the same medicine. ...
Posted by Michael Wonder on 15 Jan 2020
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
15 January 2020 - Cost-effectiveness watchdog issues a round of draft and final guidance. ...